Verrica Pharmaceuticals VRCA Stock
Verrica Pharmaceuticals Price Chart
Verrica Pharmaceuticals VRCA Financial and Trading Overview
| Verrica Pharmaceuticals stock price | 5.89 USD |
| Previous Close | 5.76 USD |
| Open | 5.87 USD |
| Bid | 4.23 USD x 200 |
| Ask | 7.36 USD x 200 |
| Day's Range | 5.66 - 6.1 USD |
| 52 Week Range | 3.28 - 9.82 USD |
| Volume | 23.77K USD |
| Avg. Volume | 103.78K USD |
| Market Cap | 101.35M USD |
| Beta (5Y Monthly) | 1.549 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.54 USD |
VRCA Valuation Measures
| Enterprise Value | 82.2M USD |
| Trailing P/E | N/A |
| Forward P/E | -4.7453213 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.727452 |
| Price/Book (mrq) | 4.0972223 |
| Enterprise Value/Revenue | 2.212 |
| Enterprise Value/EBITDA | -6.295 |
Trading Information
Verrica Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.549 |
| 52-Week Change | 6.46% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 9.82 USD |
| 52 Week Low | 3.28 USD |
| 50-Day Moving Average | 6.1 USD |
| 200-Day Moving Average | 5.9 USD |
VRCA Share Statistics
| Avg. Volume (3 month) | 103.78K USD |
| Avg. Daily Volume (10-Days) | 45.29K USD |
| Shares Outstanding | 17.18M |
| Float | 7.9M |
| Short Ratio | 4.18 |
| % Held by Insiders | 48.69% |
| % Held by Institutions | 27.87% |
| Shares Short | 412.48K |
| Short % of Float | 4.66% |
| Short % of Shares Outstanding | 2.39% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -47.96% |
| Operating Margin (ttm) | -193.40% |
| Gross Margin | 61.45% |
| EBITDA Margin | -35.13% |
Management Effectiveness
| Return on Assets (ttm) | -20.87% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 37.16M USD |
| Revenue Per Share (ttm) | 2.73 USD |
| Quarterly Revenue Growth (yoy) | 46.10% |
| Gross Profit (ttm) | 22.84M USD |
| EBITDA | -13058000 USD |
| Net Income Avi to Common (ttm) | -17826000 USD |
| Diluted EPS (ttm) | -1.1 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 20.6M USD |
| Total Cash Per Share (mrq) | 1.2 USD |
| Total Debt (mrq) | 1.44M USD |
| Total Debt/Equity (mrq) | 8.98 USD |
| Current Ratio (mrq) | 2.104 |
| Book Value Per Share (mrq) | 1.44 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -14113000 USD |
| Levered Free Cash Flow (ttm) | -12160375 USD |
Profile of Verrica Pharmaceuticals
| Country | United States |
| State | PA |
| City | West Chester |
| Address | 44 West Gay Street |
| ZIP | 19380 |
| Phone | 484 453 3300 |
| Website | https://www.verrica.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 76 |
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Q&A For Verrica Pharmaceuticals Stock
What is a current VRCA stock price?
Verrica Pharmaceuticals VRCA stock price today per share is 5.89 USD.
How to purchase Verrica Pharmaceuticals stock?
You can buy VRCA shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Verrica Pharmaceuticals?
The stock symbol or ticker of Verrica Pharmaceuticals is VRCA.
Which industry does the Verrica Pharmaceuticals company belong to?
The Verrica Pharmaceuticals industry is Biotechnology.
How many shares does Verrica Pharmaceuticals have in circulation?
The max supply of Verrica Pharmaceuticals shares is 17.18M.
What is Verrica Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Verrica Pharmaceuticals PE Ratio is now.
What was Verrica Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Verrica Pharmaceuticals EPS is -1.1 USD over the trailing 12 months.
Which sector does the Verrica Pharmaceuticals company belong to?
The Verrica Pharmaceuticals sector is Healthcare.
Verrica Pharmaceuticals VRCA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26606.51 USD — |
-0.92
|
2.04B USD — | 26554.24 USD — | 26689.53 USD — | — - | 2.04B USD — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech Global Market Composite NQGM | 2313.61 USD — |
+0.77
|
— — | 2280.63 USD — | 2314.92 USD — | — - | — — |
| US Tech Biotechnology NBI | 5918.21 USD — |
+1.91
|
— — | 5868.75 USD — | 5926.57 USD — | — - | — — |
| US Tech Health Care IXHC | 1157.68 USD — |
+2.13
|
— — | 1146.48 USD — | 1159.03 USD — | — - | — — |
- {{ link.label }} {{link}}